Perceptive Advisors LLC acquired a new position in FibroGen, Inc (NASDAQ:FGEN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,593 shares of the biopharmaceutical company’s stock, valued at approximately $462,000.

A number of other large investors have also recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its position in FibroGen by 71.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 57,502 shares of the biopharmaceutical company’s stock valued at $1,857,000 after acquiring an additional 23,875 shares in the last quarter. Great West Life Assurance Co. Can boosted its position in FibroGen by 107.0% during the 2nd quarter. Great West Life Assurance Co. Can now owns 8,694 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 4,494 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in FibroGen by 15.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 272,574 shares of the biopharmaceutical company’s stock valued at $8,805,000 after acquiring an additional 36,201 shares in the last quarter. First Trust Advisors LP bought a new stake in FibroGen during the 2nd quarter valued at $599,000. Finally, Rhumbline Advisers boosted its position in FibroGen by 11.4% during the 2nd quarter. Rhumbline Advisers now owns 68,167 shares of the biopharmaceutical company’s stock valued at $2,202,000 after acquiring an additional 6,986 shares in the last quarter. 57.43% of the stock is currently owned by institutional investors.

Shares of FibroGen, Inc (FGEN) opened at $46.40 on Monday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen, Inc has a 52-week low of $19.25 and a 52-week high of $60.15.

FGEN has been the topic of several recent research reports. Jefferies Group reaffirmed a “buy” rating and set a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 target price on shares of FibroGen in a research report on Thursday, September 14th. Mizuho initiated coverage on FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 target price on the stock. Finally, ValuEngine cut FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $65.67.

In other news, insider K Peony Yu sold 40,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.63, for a total value of $2,185,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $51.67, for a total value of $1,996,322.12. Following the completion of the sale, the chief executive officer now directly owns 3,297,655 shares of the company’s stock, valued at approximately $170,389,833.85. The disclosure for this sale can be found here. Insiders sold a total of 397,131 shares of company stock valued at $21,109,380 in the last three months. Insiders own 13.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Perceptive Advisors LLC Acquires New Position in FibroGen, Inc (FGEN)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/11/perceptive-advisors-llc-acquires-new-position-in-fibrogen-inc-fgen.html.

FibroGen Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.